First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study | Zendy

Viki Bockstal | Zendy; Georgi Shukarev | Zendy; Chelsea McLean | Zendy; Neil Goldstein | Zendy; Stephan Bart | Zendy; Auguste Gaddah | Zendy; Dickson Anumenden | Zendy; Jeroen N. Stoop | Zendy; Anne Marit de Groot | Zendy; Maria Grazia Pau | Zendy; Jenny Hendriks | Zendy; Stephen C. De Rosa | Zendy; Kristen W. Cohen | Zendy; M. Juliana McElrath | Zendy; Benoît Callendret | Zendy; Kerstin Lühn | Zendy; Macaya Douoguih | Zendy; Cynthia Robinson | Zendy

Open Access

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

Author(s) -

Viki Bockstal,

Georgi Shukarev,

Chelsea McLean,

Neil Goldstein,

Stephan Bart,

Auguste Gaddah,

Dickson Anumenden,

Jeroen N. Stoop,

Anne Marit de Groot,

Maria Grazia Pau,

Jenny Hendriks,

Stephen C. De Rosa,

Kristen W. Cohen,

M. Juliana McElrath,

Benoît Callendret,

Kerstin Lühn,

Macaya Douoguih,

Cynthia Robinson

Publication year - 2022

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0274906

Subject(s) - ebola virus , tolerability , chills , marburg virus , myalgia , ebola vaccine , regimen , medicine , placebo , randomized controlled trial , adverse effect , ebola hemorrhagic fever , immunogenicity , virology , ebolavirus , immunology , outbreak , pathology , immune system , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research